Yohei Tomita1,2, Gael Cagnone3, Zhongjie Fu1,4, Bertan Cakir1, Yumi Kotoda1, Masaki Asakage5, Yoshihiro Wakabayashi5, Ann Hellström6, Jean-Sébastien Joyal3,7, Saswata Talukdar8, Lois E H Smith9, Yoshihiko Usui10. 1. Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 2. Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan. 3. Department of Pediatrics, Pharmacology and Ophthalmology, CHU Sainte-Justine Research Center, Université de Montréal, Montreal, QC, Canada. 4. Manton Center for Orphan Disease, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. 5. Department of Ophthalmology, Tokyo Medical University Hospital, Tokyo, Japan. 6. Pediatric Ophthalmology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden. 7. Department of Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada. 8. Merck & Co., Inc., South San Francisco, CA, USA. 9. Department of Ophthalmology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA. Lois.Smith@childrens.harvard.edu. 10. Department of Ophthalmology, Tokyo Medical University Hospital, Tokyo, Japan. usuyoshi@gmail.com.
Abstract
AIMS/HYPOTHESIS: Proliferative diabetic retinopathy (PDR) with retinal neovascularisation (NV) is a leading cause of vision loss. This study identified a set of metabolites that were altered in the vitreous humour of PDR patients compared with non-diabetic control participants. We corroborated changes in vitreous metabolites identified in prior studies and identified novel dysregulated metabolites that may lead to treatment strategies for PDR. METHODS: We analysed metabolites in vitreous samples from 43 PDR patients and 21 non-diabetic epiretinal membrane control patients from Japan (age 27-80 years) via ultra-high-performance liquid chromatography-mass spectrometry. We then investigated the association of a novel metabolite (creatine) with retinal NV in mouse oxygen-induced retinopathy (OIR). Creatine or vehicle was administered from postnatal day (P)12 to P16 (during induced NV) via oral gavage. P17 retinas were quantified for NV and vaso-obliteration. RESULTS: We identified 158 metabolites in vitreous samples that were altered in PDR patients vs control participants. We corroborated increases in pyruvate, lactate, proline and allantoin in PDR, which were identified in prior studies. We also found changes in metabolites not previously identified, including creatine. In human vitreous humour, creatine levels were decreased in PDR patients compared with epiretinal membrane control participants (false-discovery rate <0.001). We validated that lower creatine levels were associated with vascular proliferation in mouse retina in the OIR model (p = 0.027) using retinal metabolomics. Oral creatine supplementation reduced NV compared with vehicle (P12 to P16) in OIR (p = 0.0024). CONCLUSIONS/ INTERPRETATION: These results suggest that metabolites from vitreous humour may reflect changes in metabolism that can be used to find pathways influencing retinopathy. Creatine supplementation could be useful to suppress NV in PDR. Graphical abstract.
AIMS/HYPOTHESIS: Proliferative diabetic retinopathy (PDR) with retinal neovascularisation (NV) is a leading cause of vision loss. This study identified a set of metabolites that were altered in the vitreous humour of PDR patients compared with non-diabetic control participants. We corroborated changes in vitreous metabolites identified in prior studies and identified novel dysregulated metabolites that may lead to treatment strategies for PDR. METHODS: We analysed metabolites in vitreous samples from 43 PDR patients and 21 non-diabetic epiretinal membrane control patients from Japan (age 27-80 years) via ultra-high-performance liquid chromatography-mass spectrometry. We then investigated the association of a novel metabolite (creatine) with retinal NV in mouse oxygen-induced retinopathy (OIR). Creatine or vehicle was administered from postnatal day (P)12 to P16 (during induced NV) via oral gavage. P17 retinas were quantified for NV and vaso-obliteration. RESULTS: We identified 158 metabolites in vitreous samples that were altered in PDR patients vs control participants. We corroborated increases in pyruvate, lactate, proline and allantoin in PDR, which were identified in prior studies. We also found changes in metabolites not previously identified, including creatine. In human vitreous humour, creatine levels were decreased in PDR patients compared with epiretinal membrane control participants (false-discovery rate <0.001). We validated that lower creatine levels were associated with vascular proliferation in mouse retina in the OIR model (p = 0.027) using retinal metabolomics. Oral creatine supplementation reduced NV compared with vehicle (P12 to P16) in OIR (p = 0.0024). CONCLUSIONS/ INTERPRETATION: These results suggest that metabolites from vitreous humour may reflect changes in metabolism that can be used to find pathways influencing retinopathy. Creatine supplementation could be useful to suppress NV in PDR. Graphical abstract.
Authors: Ignasi Barba; Marta Garcia-Ramírez; Cristina Hernández; María Angeles Alonso; Lluis Masmiquel; David García-Dorado; Rafael Simó Journal: Invest Ophthalmol Vis Sci Date: 2010-04-07 Impact factor: 4.799
Authors: Liliana P Paris; Caroline H Johnson; Edith Aguilar; Yoshihiko Usui; Kevin Cho; Lihn T Hoang; Daniel Feitelberg; H Paul Benton; Peter D Westenskow; Toshihide Kurihara; Jennifer Trombley; Kinya Tsubota; Shunichiro Ueda; Yoshihiro Wakabayashi; Gary J Patti; Julijana Ivanisevic; Gary Siuzdak; Martin Friedlander Journal: Metabolomics Date: 2015-11-18 Impact factor: 4.290
Authors: Yan Gong; Yohei Tomita; Matthew L Edin; Anli Ren; Minji Ko; Jay Yang; Edward Bull; Darryl C Zeldin; Ann Hellström; Zhongjie Fu; Lois E H Smith Journal: Metabolism Date: 2022-07-19 Impact factor: 13.934
Authors: Yan Yang; Wenyun Yue; Nan Wang; Zicong Wang; Bingyan Li; Jun Zeng; Shigeo Yoshida; Chun Ding; Yedi Zhou Journal: Front Endocrinol (Lausanne) Date: 2022-07-12 Impact factor: 6.055